TD Cowen analyst Tyler Van Buren maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV – Research Report) yesterday. The company’s ...

Advisors Asset Management Inc. trimmed its stake in Regeneron Pharmaceuticals by 7.9%, selling 443 shares in the fourth ...

Winners and the industry at large will gather at the CIO 100 Symposium & Awards this August in Scottsdale, AZ BOSTON, MA / ACCESS Newswire / ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.